![]() | |
Legal status | |
---|---|
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C20H26N4O4 |
Molar mass | 386.452 g·mol−1 |
3D model (JSmol) | |
| |
|
Bevenopran (INN, USAN) (former developmental code names CB-5945, ADL-5945, MK-2402, OpRA III) is a peripherally acting μ-opioid receptor antagonist that also acts on δ-opioid receptors and was under development by Cubist Pharmaceuticals for the treatment of chronic opioid-induced constipation.[1][2][3] It reached phase III clinical trials for this indication before being discontinued.[4][5]
| |
---|---|
Stool softeners |
|
Stimulant laxatives |
|
Bulk-forming laxatives |
|
Lubricant laxatives |
|
Osmotic laxatives |
|
Enemas |
|
Opioid antagonists |
|
Others |
|
![]() | This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it. |